Routine inducement grant for new hires — no change to company outlook. Monitor upcoming Phase 3 IMPROVE-PAH trial enrollment updates for the next material catalyst.
Price Chart
Executive Summary
Inhibikase Therapeutics granted 128,000 non-qualified stock options to two newly-hired non-executive employees as an inducement for employment, with an exercise price of $2.055 per share. The options vest over four years (25% on first anniversary, then monthly). This is a routine equity grant for hiring purposes, not a material financial event.
Key Facts
- 128,000 non-qualified stock options granted to two newly-hired non-executive employees
- Exercise price of $2.055 per share, equal to closing price on September 30, 2026
- Options vest 25% on first anniversary, then 75% in 36 equal monthly installments
- Grant made under the 2026 Inducement Equity Plan approved in March 2026
Financial Impact
128,000 options at $2.055 exercise price; no immediate cash impact or dilution beyond standard equity compensation
Risk Factors
- Clinical-stage company with no approved products; single pivotal Phase 3 trial carries binary risk
- Small inducement grant does not signal any change in business fundamentals
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374005 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 5d ago | 8-K | $1.66 | awaiting T+20 | — | $1.51 (−8.73%) |
Oct 2, 2026 23d ago | Press Release | $2.00 | awaiting T+20 | — | $1.51 (−24.25%) |
Aug 11, 2026 10w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.51 (−36.88%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.51 (−34.98%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.51 (−32.06%) |
Jul 14, 2026 14w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.51 (+26.46%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.51 (−21.50%) |
May 12, 2026 23w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.51 (−20.26%) |
May 12, 2026 23w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.51 (−20.26%) |
Apr 7, 2026 28w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.51 (−13.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers